Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin DE000BAY0017
Ticker BAYN.DE
Company BAYER
Currency
Price
Aware Investor Index (AII) 0.1969
Recommendation HOLD
P/E 20.92
ROE 6.48 %
Capitalization 72,301,293,887 $
Dividend Yield 4.23 %
P/S 1.57
AII Position 425
P/E Position 285
ROE Position 554
Capitalization Position 122
Dividend Yield Position 149
Sales 39,586,000,000 €
10-Year Average Earnings 2,977,200,000 €
Shares Outstanding 940,754,504
Equity 45,977,000,000 €
Dividend per Share 2.8 €
Industry Pharmaceutical
Country Germany
BAYER Investor Relations Web Site http://www.investor.bayer.com/en/







Sales:

YEAR MONTH AMOUNT
2018 12 39,586,000,000.00 €
2017 12 35,015,000,000.00 €
2016 12 34,943,000,000.00 €
2015 12 46,324,000,000.00 €
2014 12 42,239,000,000.00 €
2013 12 40,157,000,000.00 €
2012 12 39,760,000,000.00 €
2011 12 36,528,000,000.00 €
2010 12 35,088,000,000.00 €
2009 12 31,168,000,000.00 €

Earnings:

YEAR MONTH AMOUNT
2018 12 1,695,000,000.00 €
2017 12 7,336,000,000.00 €
2016 12 4,531,000,000.00 €
2015 12 4,110,000,000.00 €
2014 12 3,426,000,000.00 €
2013 12 3,189,000,000.00 €
2012 12 889,000,000.00 €
2011 12 1,125,000,000.00 €
2010 12 1,245,000,000.00 €
2009 12 2,226,000,000.00 €

Equity:

YEAR MONTH AMOUNT
2018 12 45,977,000,000.00 €
2017 12 36,801,000,000.00 €
2016 12 30,333,000,000.00 €
2015 12 24,265,000,000.00 €
2014 12 20,106,000,000.00 €
2013 12 13,888,000,000.00 €
2012 12 14,363,000,000.00 €
2011 12 13,888,000,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 940,754,504
2017 12 872,107,808
2016 12 832,502,808
2015 12 826,947,808
2014 12 826,947,808
2013 12 826,947,808
2012 12 826,947,808
2011 12 826,950,000

 












Bloomberg News for BAYER:



Google News for BAYER:

The Pharma Letter - 1 day ago
CRISPR Therapeutics takes over JV Casebia
Gene-editing start-up CRISPR Therapeutics and German pharma major Bayer (BAYN: DE) today announced proposed plans whereby Casebia ...
The Pharma Letter - 9 Oct 2019
Bayer and RIKEN partner for novel drug discovery
German pharma major Bayer (BAYN: DE) has entered into a strategic collaboration agreement with Japan's RIKEN Innovation Co to jointly ...
PR Newswire UK (press release) - 10 Oct 2019
Bayer G4A Partners With Wellthy Therapeutics
Bayer G4A Partners With Wellthy Therapeutics ... today announced its partnership with Bayer (BAYN: DE) through its G4A partnership initiative.
The Pharma Letter - 10 Oct 2019
Bayer opens new AI-driven research base in the UK
Germany's Bayer (BAYN: DE) has opened LifeHub UK, the latest in a series of innovation hubs focused on artificial intelligence. The UK base in ...
The Pharma Letter - 24 Sep 2019
Bayer partners on joint lab for research of new chronic lung disease ...
Germany's largest pharma Bayer (BAYN:DE) today revealed that it is investing $30 million to fund research projects in the lung disease sector ...
The Pharma Letter - 23 Sep 2019
Bayer's Vitrakvi first tumor agnostic drug to get EMA license
Vitrakvi, for which Germany's Bayer (BAYN: DE) has obtained exclusive licensing rights for global development and commercialization, has ...
The Pharma Letter - 14 Oct 2019
US FDA grants eighth indication for Xarelto
... Johnson & Johnson (NYSE: JNJ) pharma subsidiary Janssen, which has US marketing rights to the drug from Germany's Bayer (BAYN: DE).
The Pharma Letter - 25 Sep 2019
Durability data for newly-approved Vitrakvi on show
As German pharma major Bayer (BAYN: DE) looks to expand its oncology offering, the latest new data will be presented at the annual meeting ...
The Pharma Letter - 10 Oct 2019
Sanofi opens UK pharma hub
Reading is a popular area for life science companies to base their UK headquarters, with Germany's Bayer (BAYN: DE) among the other firms ...
The Pharma Letter - 8 Oct 2019
Novartis gets FDA nod for new eye drug Beovu
... but it will be going up against the might of Regeneron (Nasdaq: REGN) and Bayer's (BAYN: DE) Eylea (aflibercept). The Evaluate group has ...


Back